Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
More than 15 new obesity medications are expected to gain approval over the next five years
Primary Claim: 46% More Weight Loss According to publicly available disclosures on the company's website, Ivm Health states that "Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks." The company explicitly states this was "not a head-to-head study," meaning Ivm patients were not directly randomized against a control group in the same trial
Plus, get expert support to guide you in your journeyall for one monthly price
The drug is an experimental, weekly injection
L-carnitine is widely used by athletes and gym-goers for its role in energy metabolism
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats
US$ 26.51
US$ 21.26
US$ 20.47
US$ 21.22
